Importance Colorectal cancer (CRC) is the third most common cause of cancer mortality
worldwide with more than 1.85 million cases and 850 000 deaths annually. Of new …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.1 million new
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

Background The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus
bevacizumab showed improved outcomes for patients with metastatic colorectal cancer …

Colorectal cancer is a prevalent disease worldwide, with more than 50% of patients
developing metastases to the liver. Despite advances in improving resectability, most …

Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and
irinotecan) plus bevacizumab significantly improved progression-free survival of patients …

PURPOSE To verify whether the intensification of the upfront chemotherapy backbone with a
modified schedule of modified fluorouracil, leucovorin, oxaliplatin, and irinotecan …

Significant progress has been achieved in the treatment of metastatic colorectal cancer
(mCRC) patients during the last 20 years. There are currently numerous treatments …

Background Patients with initially unresectable colorectal cancer liver metastases might
qualify for local treatment with curative intent after reducing the tumour size by induction …